490 ARSENAL WAY, WATERTOWN, MA
Departure of Chief Accounting Officer Mark Mossler at C4 Therapeutics
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Annual Report to Security Holders
By-Laws Amendment - C4 Therapeutics Designates Exclusive Forums
Expands Long-Term Partnership Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs), Investor Presentation
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
C4 Therapeutics Advances Cemsidomide, Targets Novel Pathways
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus